The Asia Pacific human microbiome market is expected to reach US$ 207.81 Mn in 2025 from US$ 41.73 in 2017. The market is estimated to grow with a CAGR of 22.8% from 2018-2025. The growth of the market is driven by the factors such as rising chronic disease due to change in lifestyle and growing interest in human microbiome treatment approach. Whereas, stringent regulatory environment and lack of awareness about human microbiome science is likely to have a negative impact on the growth of the market in the coming years.
Probiotics, prebiotics dietary supplements and foods that contain live microbes have been studied thoroughly to assess their effects on human health.The Gut Health Congress was held in Hong Kong Asia in 2018, the conference explore in detail of diet & personalised nutrition, gastrointestinal microbiome and several case studies with regards to clinical studies, diagnostics studies, treatment methods, biomarker developments, molecular therapy and gastrointestinal diseases.
Also, the 5th Microbiome R&D and Business Collaboration Congress was held in Taiwan, Asia in March 2019, the conference focused on recent developments in gut microbiome, skin microbiome, infant, women and oral health, therapeutics, microbiome and diet. Also, many companies are designing and developing many microbiome therapies. Thus, the increasing focus on human microbiome therapies is the prime factor driving the growth of human microbiome market in the coming years.
Japan is anticipated to lead the adoptions of Human microbiome across the Asia Pacific region through the forecast period.Researchers from Japan are using the outcomes of studies on centenarians in the country to try and produce new products that will replicate the beneficial aspects of their microbiota.
The goal of the collaboration is to solve few of the major technological hurdles in advancing stem cell research. Moreover, Cykinso (Tokyo) received the US$ 2.3 million (270 million yen) funds from the Regional Health Care Industry Support Fund, develop and sell Mykinso or a test kit for intestinal flora. The company plans to use the funds for business development purposes, which include using the data collected from the intestinal flora tests to develop a system for offering nutritional guidance. Thus, the investments and the initiatives taken by the government are likely to propel the growth of the market in the forecast period.
Exhibit: Rest Of Asia Pacific Human microbiome Market Revenue and Forecasts to 2027 (US$ Bn)
ASIA PACIFIC HUMAN MICROBIOME- MARKET SEGMENTATION By Product Probiotics Foods Prebiotics Medical Foods Diagnostic Device Drugs Supplements ASIA PACIFIC HUMAN MICROBIOME- MARKET SEGMENTATION By Disease Obesity Diabetes Autoimmune Disorders Cancer Mental Disorders Others ASIA PACIFIC HUMAN MICROBIOME- MARKET SEGMENTATION By Application Therapeutics Diagnostics
By Country U.S. Canada Mexico
Companies Mentioned Enterome MicroBiome Therapeutics, LLC Rebiotix Inc. Yakult Honsha Co., Ltd. Osel Inc. Vedanta Biosciences, Inc. Metabiomics Corporate Synthetic Biologics, Inc. DuPont BiomX Ltd.
Reasons to Buy Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the human microbiome market. Highlights key business priorities in order to assist companies to realign their business strategies. The key findings and recommendations highlight crucial progressive industry trends in the global human microbiome market, thereby allowing players across the value chain to develop effective long-term strategies. Develop/modify business expansion plans by using substantial growth offering developed and emerging markets. Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it. Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Our reports have been used by over 10K customers, including:
Islet Amyloid Polypeptide - Pipeline Review, H2 2020 Summary Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food...
Myasthenia Gravis Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Myasthenia Gravis Global Clinical Trials Review, H2, 2020" provides an overview of Myasthenia Gravis Clinical trials scenario.This report provides top line data relating to the clinical trials on Myasthenia...
Raynauds Disease Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Raynauds Disease Global Clinical Trials Review, H2, 2020" provides an overview of Raynauds Disease Clinical trials scenario.This report provides top line data relating to the clinical trials on Raynauds Disease. Report...
Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2020" provides an overview of Systemic Lupus Erythematosus Clinical trials scenario.This report provides top line data relating to the...
Alopecia - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Alopecia - Pipeline Review, H2 2020, provides an overview of the Alopecia (Dermatology) pipeline landscape. Alopecia is the partial or complete loss of hair especially on the scalp...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.